<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04638543</url>
  </required_header>
  <id_info>
    <org_study_id>ABP-671-201</org_study_id>
    <nct_id>NCT04638543</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia</brief_title>
  <official_title>A Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled, Multicenter, Phase 2a Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 Monotherapy in Patients With Gout or Hyperuricemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled, dose-ranging&#xD;
      study to evaluate the efficacy, safety, and pharmacokinetics study of 6 different dose&#xD;
      regimens of ABP-671 compared with placebo. The study will consist of three sequential groups&#xD;
      with escalating total daily ABP-671 doses. Each group is further divided into two dose&#xD;
      cohorts with either QD or BID dosing. Each dose group will have 3 stages following screening:&#xD;
      Run-in, Dose Evaluation, and Follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percentage change in serum uric acid (sUA) levels</measure>
    <time_frame>Baseline to the end of the 4-week Dose Evaluation Period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean sUA</measure>
    <time_frame>Baseline to the end of the 4-week Dose Evaluation Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percentage change and change in mean sUA between cohorts</measure>
    <time_frame>Baseline to the end of the 4-week Dose Evaluation Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving sUA of &lt; 6.0 mg/dL (0.357 mmol/L), &lt; 5.0 mg/dL (0.297 mmol/L), and &lt; 4.0 mg/dL (0.238 mmol/L)</measure>
    <time_frame>Baseline to the end of the 4-week Dose Evaluation Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean sUA compared between BID and QD dosing</measure>
    <time_frame>Baseline to the end of the 4-week Dose Evaluation Period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Gout</condition>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>ABP-671</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study will consist of three sequential groups with escalating total daily ABP-671 doses. Each group is further divided into two dose cohorts with either QD or BID dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABP-671</intervention_name>
    <description>ABP-671 Tablet</description>
    <arm_group_label>ABP-671</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is able to understand the study procedures, the risks involved and willing to&#xD;
             provide written informed consent before the first study related activity.&#xD;
&#xD;
          -  Subject meets the diagnosis of gout as per the American College of Rheumatism/&#xD;
             European League Against Rheumatism (EULAR) Gout Classification Criteria or diagnosis&#xD;
             of hyperuricemia.&#xD;
&#xD;
          -  Subject has an sUA level ≥ 7.0 mg/dL at baseline.&#xD;
&#xD;
          -  Subject must be willing to discontinue any other UA-lowering medication (e.g.,&#xD;
             allopurinol, febuxostat, and probenecid) and take gout prophylaxis medication during&#xD;
             the study.&#xD;
&#xD;
          -  Body mass index (BMI) ≤ 40 kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject with a documented history of rheumatoid arthritis or other autoimmune disease.&#xD;
&#xD;
          -  Subject with any clinically significant hepatic, cardiovascular, renal, neoplastic,&#xD;
             psychiatric illness, or hematological disorders such as polycythemia vera, sickle cell&#xD;
             disease, or myelodysplastic disorder.&#xD;
&#xD;
          -  Subject with a history of alcohol or drug abuse within the past 1 year prior to&#xD;
             screening, or current evidence of substance dependence or abuse.&#xD;
&#xD;
          -  Subject with a positive test for active hepatitis B, hepatitis C infection or human&#xD;
             immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Subject with active liver disease, or hepatic dysfunction.&#xD;
&#xD;
          -  Subject with an inadequate renal function with estimated serum creatinine &gt; 1.5 mg/dL&#xD;
             (&gt; 0.133 mmol/L) or creatinine clearance &lt; 60 mL/min (by Cockcroft-Gault formula).&#xD;
&#xD;
          -  Subject with a history of malignancy within the previous 5 years with the exception of&#xD;
             non-melanoma skin cancer that has been treated with no evidence of recurrence, treated&#xD;
             cervical dysplasia or treated in situ Grade 1 cervical cancer.&#xD;
&#xD;
          -  Subject with unstable angina, New York Heart Association class III or IV heart&#xD;
             failure, myocardial infarction, stroke, or deep venous thrombosis within the last 12&#xD;
             months; or subjects currently receiving anticoagulants.&#xD;
&#xD;
          -  Subject with QT interval corrected for heart rate according to Fridericia's formula &gt;&#xD;
             470 msec (females) and &gt; 450 msec (males) during the Screening Period, confirmed by a&#xD;
             repeat assessment.&#xD;
&#xD;
          -  Subject with uncontrolled hypertension&#xD;
&#xD;
          -  Subject receiving chronic treatment with more than 325 mg aspirin per day.&#xD;
&#xD;
          -  Subject that requires or may require systemic immunosuppressive or immunomodulatory&#xD;
             treatment.&#xD;
&#xD;
          -  Subject who received any investigational therapy within 30 days or 5 half-lives&#xD;
             (whichever is longer) prior to screening.&#xD;
&#xD;
          -  Subject who is pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>+1 650-405-9853</phone>
    <email>marc.gurwith@atombp.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Paratus - Canberra Clinic</name>
      <address>
        <city>Canberra</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Leah</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paratus - Central Coast Clinic</name>
      <address>
        <city>Kanwal</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peninsula Private Hospital</name>
      <address>
        <city>Kippa-Ring</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anthony Houston</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emeritus Research - Melbourne</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Deon Smith</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paratus - Western Sydney Clinic</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Napier-Flood</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

